Compare Goodyear Tire & Rubber Co (GT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Goodyear Tire & Rubber Co trades at $4.38 (market cap $1.31B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Goodyear Tire & Rubber Co is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Goodyear Tire & Rubber Co for 58 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GT | MRVI | |
|---|---|---|
Market Cap | $1.31B | $972.90M |
Volume | 8,331,802 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $9.00 |
52-Week Low | $4.38 | $2.83 |
Typical Hold Time | 58 Days | 0 Days |
Enterprise Value | $8.66B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Goodyear Tire & Rubber Company (GT) trades at $4.38, down 2.45% on the day, reflecting persistent bearish technical momentum. The stock shows deeply discounted valuation ratios, including a P/E of 4.69 and P/B of 0.46, but faces significant fundamental challenges with a net income margin of -14.37% and negative ROE of -63.93% for 2025. Recent earnings have been mixed, with Q2 2026 beating expectations but still posting a loss. Cash flow trends show modest improvement, with net cash flow turning positive in 2025 and 2026. Analyst sentiment is mixed, with a consensus price target of $8.00 implying substantial upside, though technical indicators remain bearish overall.
Outlook: GT presents a high-risk, high-reward opportunity. The stock is fundamentally undervalued, and successful execution of its restructuring and margin expansion strategy could drive significant appreciation toward the analyst target. However, persistent losses, high debt, and competitive pressures pose substantial risks. Investors should weigh the potential for a turnaround against the company's current financial instability and bearish market sentiment.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
